Skip to content

Cencora COR Estimated Litigation Liability, Noncurrent

Estimated Litigation Liability, Noncurrent at other companies

McKesson logo
McKessonMCK
$5.09B-9.1%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX

Other financials

Income statement

See full
Revenue$78.4B+3.8%
Gross profit$3.6B+17.3%
Operating income$1.1B+10.3%
Net income$1.6B+129%
EPS (diluted)$8.40+128%

Balance sheet

See full
Cash & equivalents$2.2B+10.0%
Total debt$12.2B+71.9%
Total equity$3.4B+235%
Total assets$81.7B+14.7%

Cash flow

See full
Operating cash flow-$2.3B+15.2%
CapEx$165.6M+28.3%
Free cash flow-$2.4B+14.2%

Valuation

See full
Market cap$55.06B-0.1%
Enterprise value$65.06B+6.5%
P/E15.3×+3.1×
P/S0.2×0.0×

Profitability

See full
Gross margin3.8%+0.4pp
Operating margin0.8%0.0pp
Net margin0.6%-0.1pp
FCF margin1.1%+1.0pp

Returns & leverage

See full
Return on equity130.6%-99.8pp
Debt / equity3.6×-3.4×
Current ratio0.9×+0.1×

Where this comes from

Reported directly by Cencora in its filing.

Tagged under the XBRL concept us-gaap:LitigationReserveNoncurrent.

The official record: Cencora’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cencora's estimated litigation liability, noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cencora's estimated litigation liability, noncurrent?
Cencora (COR) reported estimated litigation liability, noncurrent of $3.86B in Q1 2026.
How has Cencora's estimated litigation liability, noncurrent changed year-over-year?
Cencora's estimated litigation liability, noncurrent decreased by 10.0% year-over-year, from $4.28B to $3.86B.
What is the long-term trend for Cencora's estimated litigation liability, noncurrent?
Over 4 years (2021 to 2025), Cencora's estimated litigation liability, noncurrent has grown at a -10.2% compound annual growth rate (CAGR), from $5.96B to $3.88B.
What does estimated litigation liability, noncurrent mean?
This represents the estimated long-term liability for ongoing legal disputes or litigation that is not expected to be resolved within the next year. It reflects management's best estimate of potential financial outflows related to legal settlements or judgments. This is a critical risk metric for companies in highly regulated industries like pharmaceutical distribution.